PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

  1. Quiñonero, F.
  2. Mesas, C.
  3. Muñoz-Gámez, J.A.
  4. Jiménez-Luna, C.
  5. Perazzoli, G.
  6. Prados, J.
  7. Melguizo, C.
  8. Ortiz, R.
Zeitschrift:
Biomedicine and Pharmacotherapy

ISSN: 1950-6007 0753-3322

Datum der Publikation: 2022

Ausgabe: 155

Art: Artikel

DOI: 10.1016/J.BIOPHA.2022.113669 GOOGLE SCHOLAR lock_openOpen Access editor